

Conquer Cancer through AI

DISCLAIMER

This presentation has been prepared by Lunit Inc. solely for information purposes. The information contained in this presentation has not been independently verified. No representation or warranty express or implied is made as to, and no reliance should be placed on, the fairness, accuracy, completeness or correctness of the information or any opinion contained herein. The information contained in this presentation should be considered in the context of the circumstances prevailing at the time and will not be updated to reflect material developments that may occur after the date of the presentation. Neither Lunit Inc. nor any of its affiliates, officers, directors or advisors shall have any liability whatsoever (in negligence or otherwise) for any loss arising from any use of this presentation or its contents or otherwise arising in connection with this presentation. This presentation is being communicated only to persons who have professional experience in matters relating to investments and to persons to whom it may be lawful to communicate it (all such persons being referred to as “relevant persons”). This presentation is only directed at relevant persons and any investment or investment activity relating to this presentation is only available to relevant persons or will be engaged in only with relevant persons. Solicitations resulting from this presentation will only be responded to if the person concerned is a relevant person. Other persons should not rely or act upon this presentation or any of its contents. This presentation does not constitute or form part of an offer, invitation or recommendation to purchase or subscribe for any securities, and no part of it shall form the basis of or be relied upon in connection with any contract, commitment or investment decision in relation to any securities. No money, securities or other consideration is being solicited, and, if sent in response to this presentation or the information contained herein, will not be accepted. The presentation may contain statements that reflect Lunit Inc.’s beliefs and expectations about the future. These forward-looking statements are based on a number of assumptions about the future, some of which are beyond Lunit Inc.’s control. Such forward-looking statements are subject to certain risks and uncertainties that could cause actual results to differ materially from those contemplated by the relevant forward-looking statements. Lunit Inc. does not undertake any obligation to update any forward-looking statements to reflect events that occur or circumstances that arise after the date of this presentation. Certain data in this presentation was obtained from various external data sources, and Lunit Inc. has not verified such data with independent sources. Accordingly, Lunit Inc. makes no representations as to the accuracy or completeness of that data, and such data involves risks and uncertainties and is subject to change based on various factors. You agree to keep the contents of this presentation strictly confidential. All or any part of this presentation may not be taken away, reproduced, redistributed or retransmitted in any manner. By attending this presentation, you are agreeing to be bound by the foregoing limitations.

About Lunit

Since 2013 | 1st Generation Medical AI Company | Listed in KOSDAQ since 2022

Global Investors

Backed by leading global investors

- Raised \$122M while unlisted
- 12% of global shareholders after IPO
- Top 10% of KOSDAQ listed 1,800 companies in Korea

Foreign investment = \$73M 60%

Global Partners

Established partnerships with industry giants

Chosen by leading medical device companies

Chosen by leading bio companies

Multiple global pharmas

Industry Leader

Best-in-class AI technology and products

- Unprecedented "AA-AA" highest level in technology assessment among healthcare companies
- Best performance proven by direct comparison with global competitors in various studies

한국경제 - www.hankyung.com > article
의료 AI 기업 루닛, AA-AA'로 기술평가 통과
바이오타임즈 - 2021.06.14, 루닛 제공 올해 코스닥 시장 상장을 추진하는 의료 인공지능 루닛, 기술성 평가 역대 최고 등급 'AA-AA' 획득한 기술력은?

Commercial Success


Successfully scaling out revenue growth

- High revenue growth with 173% CAGR (2019 - 2025)
- Lunit INSIGHT (X-RAY) → First company globally to exceed \$10M in sales
- Lunit International (former "Volpara") revenue consolidation

Unit : \$ Million (1\$=1,400₩)

Year	Revenue (\$ Million)
2019	0.1
2020	1.0
2021	4.7
2022	9.9
2023	17.9
2024	38.7
2025	59.4
2026 (1H)	32.7

Core Competence



Best-in-Class A.I.

Global leader in AI technology

- Top-tier proprietary AI technology
- 30+ papers presented in top AI conferences
- Large-scale medical data for R&D (N = +4 million cases)

Top Ranked in AI Competitions

2015 Main Task (CLS-LOC) IMAGENET	1	Microsoft	
	5	Lunit	
	7	Google	
2016 MICCAI Grand Challenge Tumor Proliferation Assessment	1	Lunit	
	2	IBM	
	3	Microsoft	
2017 Camelyon CAMELYON17	1	Lunit	
	2	Harvard Univ	
	3	Eindhoven Univ. of Tech	



Global Recognition

International spotlight

- The **only Korean company** spotlighted by World Economic Forum, CB Insights



2020 / 2022 - 2025
TECHNOLOGY PIONEER /
GLOBAL INNOVATOR /
ASSOCIATE PARTNER




2017
CB Insights
AI 100



2019 / 2020 / 2021
CB Insights
DIGITAL HEALTH 150





Medical Expertise

Industry leading clinical studies

- 15+ full-time board-certified physician
- 10+ million medical data collected for AI training
- Strong academic validation leading to high credibility

+590 Publications in Major Peer-reviewed Journals & Abstracts




+100 Research Partnerships




Conquer Cancer through AI

Increase cancer survival through AI-powered cancer diagnosis and treatment





2026 INVESTOR RELATIONS



Lunit INSIGHT MMG®



Lunit INSIGHT CXR®

Product Roadmap | Beyond cancer risk prediction to autonomous AI

Current

AI-CAD

- Final clinical decision: physicians



Lunit INSIGHT®

Risk Assessment

AI-based Risk Prediction

- Hybrid AI model combining EMR data with synthetic mammography (DBT) images




Lunit International X Prognosia Health AI

Lunit INSIGHT®
Risk Assessment Product

Foundation Model

AI Customization

- Periodic updates of the AI core model
- AI customization using data provided from each site





Improve AI accuracy
across all customers

Autonomous AI

Autonomous AI in Cancer Screening

- Cost efficiency maximized through AI
- Near-perfect accuracy achievable through large-scale learning
- Final clinical decision: AI**

Expected Performance with Autonomous AI



Artificial Intelligence A.I

Higher Reading Accuracy

Better performance than specialists, proven in major studies

Evidence

Extensively
validated
through studies

+390

Studies/abstracts

THE LANCET
Digital Health

JAMA Oncology

Radiology

JAMA
Network | Open.

RSNA

SCIENTIFIC
REPORTS

Clinical
Infectious
Diseases

European
Radiology

BIR
The British
Institute of
Radiology

BMC
Pulmonary Medicine

AJR

ACTA RADIOLOGICA

JTD


THE LANCET Regional Health
Americas



EUROPEAN RESPIRATORY journal
FLAGSHIP SCIENTIFIC JOURNAL OF ERS

Performance

Clinically proven to show excellence in medical image analysis




CXR reference : Ju Gang Nam, "Development and Validation of Deep Learning-based Automatic Detection Algorithm for Malignant Pulmonary Nodules on Chest Radiographs", *Radiology* Vol. 290, No. 1(2018):218-228, doi:10.1148/radiol.2018180237
MMG reference : Hyo-Eun Kim, "Changes in cancer detection and false-positive recall in mammography using artificial intelligence: a retrospective, multireader study", *The Lancet Digital Health* Vol 2, No. 3(2020):e138-e148, doi:10.1016/S2589-7500(20)30003-0


Real World Evidence Building solid evidence through prospective studies

Study Method

What is prospective study?



Outcome is measured after the baseline state of the subjects is determined and controlled intervention applied.



Higher possibility to receive **reimbursement** if backed by prospective studies

Lunit INSIGHT CXR

Flagship prospective CXR study

10,476 Patients with chest X-Ray RCT study on 'lung nodule detection rate' at Seoul National University Hospital (Korea)

Outcome	Detection rate of actionable lung nodules	Detection rate of malignant lung nodules
A Group (n=5238) Radiologist + AI	31 (0.59%)	8 (0.15%)
B Group (n=5238) Radiologist only	13 (0.25%)	0 (0.0%)

Radiology
Large-scale Prospective RCT*

Lunit INSIGHT MMG

*Randomized Controlled Trial

: Research method in which subjects are randomly divided into control and experimental groups for comparison

Flagship prospective MMG study

55,579 women screened for breast cancer Study on 'Double Reading' by Karolinska Institutet (Sweden)

Outcome	Detection rate of cancer per 1,000 women	Recall rate per 1,000 women
1 Radiologist + Lunit INSIGHT MMG	4.3	28
2 Radiologists	4.1	29.3
Lunit INSIGHT MMG	4.1	15.5

THE LANCET Digital Health
Large-scale Prospective Study

Current Commercialization Status

Usage

Number of paying sites worldwide ¹

+8,300

Portion of revenue from
Overseas 1H 2026

95%

Lunit Users among
Top 10 Hospitals in Korea

10

Chest X-Ray exams in Korea²
Analyzed by Lunit INSIGHT CXR 2024

20%

Lunit INSIGHT MMG Users among
47 Large Hospitals in Korea 2025

57%

Partner Testimonials

“First AI company collaboration for our x-ray business”

— General Manager K***



“This is actually **out first AI company collaboration for our x-ray business. The offering will be available on all of GE digital, fixed, and mobile, and even fluoroscopy.** Leveraging the long-term established expertise, that GE has on x-ray equipment in combination with Lunit’s technology will help to keep up with the customer needs, care deeply about patients and diagnosing physicians or radiologists.”

“Felt very high customer satisfaction”

— Global Marketing Manager M***

FUJIFILM

“In Japan especially, many of the elder people cannot move from home to the clinic to take x-ray. Our x-ray with Lunit AI can visit to take x-ray immediately at home, so it is a significant difference. After we used Lunit AI in the market, I didn’t have any complaints. From Fujifilm’s standpoint, whatever AI lunit made has a very high quality, so **we would want to implement it in our x-ray system or PACS system.** Customers have already started to use AI and expect more support.”

“Lunit has both strong clinical record and national scalability”

— Global Software Product Manager P***



“**Lunit has a strong clinical validation track record and is registered in Europe and also more than 19 countries, making it an excellent partner for developing solutions that bring our customers intelligent and definitive answers to their daily needs.** We believe that the integration of Lunit’s AI in Agfa’s advanced medical imaging workstation will help facilitate more effective clinical workflows in various hospital situations.”

1) Excludes demo and research use; only commercial sales

2) Source: KOSTAT.go.kr Appx. 47M Chest X-ray exams performed annually in Korea

Key Success Factor: Proven to Be Best-in-Class

Accuracy

Superior Performance

JAMA Oncology

Salim, et al. JAMA Oncol. 2020 Aug 27.

IF 24.799%



Comparing 3 Commercial Mammography AI

Retrospective analysis of 8 years of mammography screening
Compared AI screening performance with data from 739 breast cancer-diagnosed women and 112,924 healthy women

	Lunit	Company A	Company B
AI	Lunit INSIGHT ^{MMG}	Algorithm A	Algorithm B
Sensitivity	81.9%	67.0%	67.4%
Accuracy (ROC AUC)	95.6%	92.2%	92.0%

1) Impact factor, Top 7 among Oncology Journals



Proven superior performance compared to competitors

Research

Robust Research (SCIE Journals²⁾)

Modality	Company (Country)	# of Journals
Chest X-Ray	Lunit (South Korea)	69
	Qure.ai (India)	22
	Annalise.ai (Australia)	10
	Oxipit (Romania)	3
	Zebra (Israel)	0
	Others (>10)	None
Mammography	Lunit (South Korea)	77
	ScreenPoint (France)	45
	DeepHealth (USA)	3
	Zebra (Israel)	1
	Others (>10)	None


2) SCIE (Science Citation Index Expanded): Citation index originally produced by the Institute for Scientific Information and created by Eugene Garfield



Robust research with strong clinical evidence in peer-reviewed journals

Partnership

Larger Market Access



Access to 50% of market share through global partnership

Next Step | Becoming global standard of care by B2G expansion and successful reimbursement

B to G

National Cancer Screening Programs

Reimbursement

Active Reimbursement in Japan/Korea,
Expanding into Other Markets

Direct Sales

Expansion into Direct Sales

First Case

Selected into Australia's National Breast Cancer Screening Program



BSNSW (BreastScreen New South Wales)

: A free national breast cancer screening program in NSW (MMG every 2 years to women over 40). The first case globally in which an AI-based solution is being applied in a national cancer screening program.

Expansion

B2G 사업 수주 현황 (누적)



Europe

AI can reduce burden caused by Double Reading in Europe

Outcome	Detection rate of cancer per 1,000 women	Recall rate per 1,000 women
1 Radiologist + Lunit INSIGHT MMG	4.3	28
2 Radiologists	4.1	29.3
Lunit INSIGHT MMG	4.1	15.5


Possibility of reimbursement in Europe

EU, 암 정복 위해 우선 '조기 진단'에 힘 쓴다
"2025년까지 대상 인구 90% 유방암·자궁경부암·결장 직장암 검진 받을 수 있도록 한다"

최윤수 기자 | jysc0229@yakup.com | 기자가 쓴 기사 더보기 | 일출 2022.08.29 06:00 | 수정 2022.08.29 06:01

Korea

Government Regulation / Support




Eligible to enter the **non-benefit reimbursement market** from
Lunit INSIGHT CXR: 2024.03 ~
Lunit INSIGHT MMG: 2024.3Q ~

매일경제 2023.04.04. 네이버뉴스
혁신의료기기 시장에 선진입 후 평가받는다... '혁신급'도 도입
우선 시장에 진입하게 해달란 업계 목소리가 있었다. 복지부 관계자는 "이번 선진입, 후평가 안
은 의료법·국민건강보험법 등 법률 개정과 사회적 논의가 필요한 사항으로, 단계적으로 혁신...

혁신 의료기기 규제완화 확대... 민간 정부 R&D 10조원까지 확대
등 혁신 기술 의료기기가 신속히 시장에 진입할 수 있도록 전문 평가 및 유예 제도를 확대하는 등
의 방식으로 규제가 완화된다. 아울러 국내 의료기기에 향후 5년간 민간과 정부가 연구개발(R...

Direct Sales



Indirect Sales

Modality Vendors

BM - CAPEX Model
Payment per device



PACS Vendors

BM - OPEX Model
Payment per image




Lunit x Lunit International

Lunit Acquires Lunit International (former "Volpara") (May, 2024)

Lunit International

3,600+
Customers
40%+ of US
Mammo images
covered



Reinforce

Reinforce

...

Reinforce

Reinforce

Data



Lunit

AI

Future Direction

Lung cancer screening

XX cancer screening

⋮

Expand
Data-AI flywheel model
in all cancer screening

Lunit International → Value → Lunit

Lunit → Value → Lunit International

- Stable revenue (>\$30m in ARR in 2024)
- Large-scale data for training (imaging + clinical data)
- Distribution channel in US for Lunit INSIGHT
- KOL engagement in US for autonomous AI
- Enable business development for lung and other cancer screening product suites



- Boost AI capabilities to strengthen all products
- Synergy with Lunit INSIGHT enables faster market penetration of LIL products
- Distribution of LIL products in non-US territories
- Enable development of lung cancer and other cancer related screening

Lunit X Lunit International

Strong Revenue Growth Driven by Lunit x Lunit International Synergy


Accelerated and Sustained Revenue Growth in Cancer Diagnostics Expected from Lunit x Lunit International Synergy

Revenue Trend in Cancer Screening

Overseas


Korea

Unit : \$ Million
(1\$=1,400₩)



Direct to Patient Business Model | SecondRead AI Gaining Strong Traction in US Market


Traditional Business Model



New Business Model

Provider offers SecondReadAI™ direct to patients for an out-of-pocket fee at registration or point of care.

Revenue per analysis is **x10-20**



SecondReadAI™ Expected Opt-in Rate > 50%
Powered by Lunit

Southtowns RADIOLOGY a Rezolut partner

SecondReadAI™

Powered by Lunit

Ask us about AI-enhanced mammography interpretation

A second digital review that analyzes every pixel to detect abnormalities that may be difficult for the human eye to detect.

Proven in clinical studies to increase early-stage breast cancer detection by as much as 15%.

A second analysis using advanced technology for greater peace of mind.

YOU'RE WORTH IT.

Learn more about adding SecondReadAI to your annual mammogram

Lunit Cancer Screening


Lunit INSIGHT Risk Assessment Product

Establishing a new standard for early breast cancer detection and personalized preventive care

Before : Risk Assessment Solutions

Lunit International 'Risk Pathways'

- A risk assessment software designed to identify and manage high-risk patients for breast, lung, colorectal, gastric, and pancreatic cancer
- Assesses risk based on **EMR data** such as family history, genetic information, lifestyle, etc
- Personalized prediction is **limited** due to the **absence of imaging information**




Prognosis Business Strengths

- **FDA (Breakthrough Device Designation):** Recognized for technological and clinical value, enabling accelerated market entry
- **Optimized for U.S. market:** Validated with U.S. SEER-based data and aligned with major guidelines (NCCN, USPSTF, ASCO)

After : Integrated Risk Prediction Solutions



Lunit
International
(EMR data)



Prognosis
(Imaging data)




Lunit INSIGHT Risk Assessment Product

Hybrid AI model combining EMR data with synthetic mammography (DBT) images

Strength: Leverages objective imaging data to provide more precise and individualized 5-year breast cancer risk assessments.

Product Development Timeline




**A New Standard
for Personalized
Screening**

Foundation Model


Current: Unified AI Model

- **Single AI model** for all customer
- AI accuracy varies depending on each customer's data and AI training data




Overcoming Limitations Through AI Customization

- Maintain high AI accuracy for each customer through customized AI models



Lunit Cancer Screening


Customization AI for Autonomous AI Requires Platform Approach of Data-AI Flywheel Ecosystem




Our Future is Autonomous AI

Path to Autonomous AI: Customization of AI Model for Each Customer


Limitation of current AI applications
: Single AI model for all customer




AI customization using data provided from each site



Expected Benefits of Autonomous AI




Expected Performance with Autonomous AI






2026 INVESTOR RELATIONS



Lunit SCOPE IO



Lunit SCOPE uIHC

Personalized Approach Is Key to Cancer Treatment

High Complexity in Cancer



Even cancers in the same organ have different biological characteristics and prognoses.

Morphological Type Mutation Type Tumor Heterogeneity

1,000+ **1,000+** **10+**


WHO's Morphological Classification

Gene Mutations Causing Cancer




KEY: Personalized Treatment by Biomarkers


Traditional: One general treatment for all cancer patients



Now & Future: Biomarker-based personalized treatment



Lunit SCOPE: AI-powered Biomarkers for Major Cancer Drugs




Lunit SCOPE Overview


Lunit SCOPE: AI-powered Biomarkers for Major Cancer Drugs



 **Lunit SCOPE IO®**



 **Lunit SCOPE uIHC**



 **Lunit SCOPE GP**

Purpose	Biomarkers for IO therapeutics	Biomarkers for ADCs therapeutics	Screening for multiple biomarkers
Key Features	Identification of predictive tissue/cell features (H&E)	Quantification of protein expression level/pattern (IHC)	End-to-end prediction of specific genomic mutations
Potential Applications	CDx biomarkers for IO drugs Complimentary biomarkers	CDx biomarkers for ADC drugs	Prescreening genomic mutations Patient enrollment in clinical trials
Related Therapies	Immune Checkpoint Inhibitors	Targeted therapy - mostly ADCs	Targeted therapy - small molecules

Proven to Be Effective in Pharma Clinical Trials

+20 Global Big Pharma

Currently discussing research agreement/
collaboration with leading global pharmas

Monotherapy : 3x more responsive when using Lunit SCOPE IO

Phase 1 : "multiple cancer", anti-PD-(L)1 Inhibitor

		Group	N	ORR
		All analyzed set	32	21.9%
Pharma 	Anti-PD-(L)1	Lunit SCOPE(+)	8 (25%)	62.5%
	Lunit SCOPE IO*	Lunit SCOPE(-)	24 (75%)	8.3%

Combotherapy : 2x more responsive when using Lunit SCOPE IO

Phase 1/2 : Colorectal cancer (MSS), TGF-beta Inhibitor + anti-PD-(L)1 Inhibitor

		Group	N	ORR
		All analyzed set	31	12.9%
Pharma 	TGF-beta inhibitor	Lunit SCOPE(+)	16 (51.6%)	25.0%
	Anti-PD-(L)1	Lunit SCOPE(-)	15 (48.4%)	0%

Monotherapy : 2.6x more responsive when using Lunit SCOPE IO

Phase 2 : Rectal cancer, Chemoradiotherapy + anti-PD-(L)1 Inhibitor

		Group	N	pCR
		All analyzed set	38	28.9%
Pharma 	Anti-PD-(L)1	Lunit SCOPE(+)	8 (21%)	75.0%
	Lunit SCOPE IO*	Lunit SCOPE(-)	30 (79%)	16.7%

Combotherapy : 1.6x higher PFS when using Lunit SCOPE IO

Phase 2 : Nasopharyngeal cancer, Chemotherapy + anti-PD-(L)1 Inhibitor

		Group	N	PFS rate (%)
		All analyzed set	24	32.2%
Pharma 	Anti-PD-(L)1	Lunit SCOPE(+)	12 (50%)	52.1%
	Chemotherapy	Lunit SCOPE(-)	12 (50%)	0%

Key Clinical Studies for Lunit SCOPE

Lunit SCOPE IO®

High Prediction of Response to Immunotherapy in Lung Cancer

[Regardless of PD-L1 status]
ORR - 2.5 times higher

Patient Group	Overall Response Rate
Lunit SCOPE IO Positive	26.8%
Lunit SCOPE IO Negative	11.3%

[PD-L1 1~49% Group] ORR - 6 times higher

Patient Group	Overall Response Rate
Lunit SCOPE IO Positive	22.8%
Lunit SCOPE IO Negative	3.9%

Expanding Lunit SCOPE IO to All Cancer Types

[All cancer types] ORR - 1.7 times higher

Patient Group	Overall Response Rate
Lunit SCOPE IO Positive	26.3%
Lunit SCOPE IO Negative	15.8%

Lunit SCOPE uIHC

uIHC based AI Quantification
for Various Antibodies Protein Expression Analysis

Staining (Antibodies)	No. of Negative TC / Positive TC	Cell detection performance (mF1)	TPS classification performance (Accuracy)
TROP2	1243 / 3289	78.9%	94.0%
MET	3493 / 1134	80.5%	96.0%
Claudin 18.2	2927 / 74	72.7%	94.0%
DLL3	2973 / 3	68.9%	100%
HER3	2768 / 138	60.9%	94.0%
FGFR2	2358 / 438	50.8%	81.0%
E-Cadherin	443 / 912	79.2%	90.0%

uIHC based AI Quantification
Shows Predictive Power in HER2

Group	n	ORR, N (%)	PFS, months, median (95% CI)	HR (95% CI)	P
AI-H3-low	11	0	1.4 (1.3-NR)	Ref	< .001
AI-H3-high	19	8 (42.1)	4.4 (4.0-12.0)	0.12 (0.04-0.38)	


Survival Rate: 3x Gap

Lunit SCOPE GP

Prediction of Various Lung Cancer
Driver Mutations by Lunit SCOPE GP


	External Validation set			
	N (%)	AUC	Sensitivity	Specificity
EGFR-mt	224 (28.3)	0.723	75.5%	52.6%
KRAS-mt	130 (16.4)	0.721	86.2%	22.5%
ALK-tr	46 (5.8)	0.738	39.1%	81.8%
ROS1-tr	62 (7.8)	0.609	14.5%	70.6%
RET-tr	11 (1.4)	0.683	18.2%	96.4%
MET-ex	12 (1.5)	0.849	83.3%	74.4%
All-WT	277 (35.0)	N/A	15.9%	99.2%

EGFR Mutation Subtype Prediction
by Lunit SCOPE GP



Business Model

Paired with pharma's drug, to generate high sales by active testing before treatment



Commercialization Roadmap

From Pharma Research to Companion Diagnostics (CDx)

Step 1: Biopharma Engagement

Pilot or Bake-off Study

Active Pharma

15+

Step 2: Broader Use, RUO Service

Translational Research

Active Pharma

10+

Step 3: As a CTA

Clinical Trial Enrollment

Apply SCOPE in Clinical Trials
Screening patients with SCOPE for patient enrollment in clinical trials OR Analyzing existing clinical trial data with SCOPE




Regulatory Approval as CDx

FDA Approval

Drug
Proof of efficacy

Lunit SCOPE®
CDx proof of efficacy

CDx Sales for Clinical Use



Per Test Payment for Clinical Use


Research Revenue: Per Analysis Payment from Pharma Partners

Global Top20 Pharma of 2024
based on oncology drug revenues

1	Merck	11	Astellas
2	BMS	12	Incyte
3	Roche	13	Takeda
4	J&J	14	Glaxo
5	AZ	15	Sanofi
6	Novartis	16	BeiGene
7	Pfizer	17	Daiichi
8	Amgen	18	Bayer
9	Eli Lilly	19	GSK
10	Abbvie	20	Teva


We are
engaged with

15+

Lunit SCOPE® Revenue Trend
(RUO Sales)Clinical collaborations with big pharma
to generate research revenue

2027 ~ : FDA Approval

Exponential increase in revenue
Approved as CDx product;
authorized for reimbursement



Lunit SCOPE® Market

Cancer Biomarker Market

\$27B+


Target Market
\$10B+

Strong Traction with Major Industry Vendors for Future Distribution Scalability

Pathology Labs

Top 5 Anatomic Pathology Labs Based on Revenue

1	Labcorp
2	Quest
3	Sonic
4	Neogenomics
5	Pathgroup



Staining Component

Antibody Manufacturer



Digitization Component

Scanner Manufacturer



Viewing Component

Path-PACS Manufacturer



Among Top5 Labs,
We are engaged with
- as well as other key CROs

2

Among Top5 antibody makers,
We are engaged with

2

Among Top5 platforms,
We are engaged with

3


Most pathology scanners
are compatible with
Lunit's AI

5+

Next Steps

Cover All Types of Drugs

Lunit SCOPE will be able to cover all types of oncology drugs



Source : Maximize market research PVT. LTD

Multi-omic Biomarkers

Lunit SCOPE will deliver optimal cancer treatment through multi-omics analysis



Genomics



Pathomics



Radiomics



Metabolomics





Proteomics

Comprehensive Data Analysis

"Multi-omics"

Drug Discovery & Development

Lunit SCOPE biomarkers shall be applied to drug discovery/development



Lunit SCOPE®



Conquer Cancer through AI-powered Precision Medicine

Having strong faith that a data-driven approach is the future,

Lunit will be the center of cancer care
Globally become the new standard of care



THANK YOU

Appendix

Consolidated Financial Statements

Statement of Financial Position

Unit:KRW million

	1H 2026	2025	2024	2023
Current Asset	217,163	55,620	111,882	230,418
Non Current Asset	328,107	314,292	321,032	37,503
Total Assets	545,271	369,912	432,914	267,921
Current Liabilities	196,795	212,212	252,413	12,794
Non Current Liabilities	16,834	20,267	17,767	20,017
Total Liabilities	213,629	232,479	270,180	32,811
Capital Stock	37,229	14,628	14,471	14,351
Additional paid-in Capital	746,774	549,031	526,646	515,518
Others	15,128	(121)	(278)	182
Retained earnings (Accumulated Deficit)	(467,489)	(426,105)	(378,104)	(294,941)
Total shareholders' equity	331,642	137,433	162,735	235,110

Source: DART, Company K-IFRS Audited

Income Statement

Unit:KRW million

	1H 2026	2025	2024	2023
Operating Income	45,766	83,129	54,180	25,080
Operating Cost	74,728	166,233	122,127	67,297
Operating Income(Loss)	(28,962)	(83,104)	(67,947)	(42,217)
Financial Income	14,841	89,254	19,202	10,257
Financial Expenses	26,330	53,050	34,743	4,764
Other Income	38	151	107	80
Other Expenses	62	85	121	119
Income(Loss) before Tax	(40,476)	(46,835)	(83,502)	(36,764)
Tax Expenses(Income)	891	555	(806)	35
Net Income(Loss)	(41,367)	(47,390)	(82,695)	(36,798)

Source: DART, Company K-IFRS Audited